Actively Recruiting
Evaluating Safety and Immune Response of Different Doses of Adsorbed Acellular Pertussis Two-Component Diphtheria-Tetanus Vaccine in People 10 Years and Older
Led by Changchun BCHT Biotechnology Co. · Updated on 2026-10-26
420
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the immune response and safety of different doses of an adsorbed acellular pertussis two-component diphtheria-tetanus combined vaccine in people aged 10 years and older. This Phase II randomized, blinded, placebo-controlled study aims to better understand how the vaccine works to prevent pertussis whooping cough, diphtheria, and tetanus infections. Participants will receive an intramuscular injection of either a low dose vaccine, a high dose vaccine, or a placebo. The preferred injection site is the deltoid muscle of the upper arm. The study compares these three groups to assess immune responses and safety profiles. The vaccination is a single dose, and participants are monitored for 30 days following injection. During the study, participants will be evaluated for immune responses by measuring antibody levels against diphtheria, tetanus, pertussis toxin, and filamentous hemagglutinin 30 days after vaccination. Safety is assessed by recording any adverse events related to the treatment within the same period. Participants are required to complete follow-up visits and comply with the study protocol. The total study duration extends until August 2027, with primary outcome measurements completed by September 2026.
CONDITIONS
Brief Title
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Research Team
C
Chen Xin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here